Immunotherapy targeting leukemia-associated antigens has shown promising results.
Because of the heterogeneity of leukemia, vaccines with a single peptide have elicited only …

Targeted T-cell therapy is a potentially less toxic strategy than allogeneic stem cell
transplantation for providing a cytotoxic antileukemic response to eliminate leukemic stem …

With the aim to identify cyclin B1-derived peptides with high affinity for HLA-A2, we used
three in silico prediction algorithms to screen the protein sequence for possible HLA-A2 …

The receptor for hyaluronic acid-mediated motility (RHAMM) is a tumor-associated antigen
in chronic lymphocytic leukemia (CLL). CD8+ T cells primed with the RHAMM-derived …

Mantle cell lymphoma (MCL) accounts for 5–10% of all non-Hodgkin lymphomas and has
the worst prognosis among all lymphomas. The hallmark of MCL is at (11; 14) translocation …

In the present study, we attempted a comprehensive analysis of human leukocyte antigen
(HLA) class I-bound peptides presented on adult T-cell leukemia (ATL) cells by the latest …

Cyclin D1 is over-expressed in various human tumors and therefore can be a potential
oncogenic target antigen. However, only a limited number of T cell epitopes has been …

Cyclin A1 is a promising antigen for T cell therapy being selectively expressed in high-grade
ovarian cancer (OC) and acute myeloid leukemia (AML) stem cells. For adoptive T cell …

Purpose: Cyclin D1, a key cell cycle regulator, is overexpressed in multiple types of cancer.
Such tumor-associated genes may be useful targets for cancer immunotherapy …

Cyclin‐A2, a key cell cycle regulator, has been shown to be overexpressed in various types
of malignancies with little expression in normal tissue. Such tumor‐associated genes …